An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).

Xinan Sheng,Zhisong He,Weiqing Han,Aiping Zhou,Hong Luo,Yanxia Shi,Changlu Hu,Ziling Liu,Hongqian Guo,Xin Yao,Benkang Shi,Ji-Yan Liu,Zhigang Ji,Jianming Guo,Yi Hu,Shi Ying Yu,Guohua Yu,Jianming Ying,Jianmin Fang,Jun Guo

An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).

2021

4584Background: There is still urgent medical needs in the patients with locally advanced or metastatic urothelial cancer (mUC) post to the failure of at least one line chemotherapy. RC48-ADC, a no...

Keywords:

locally advanced
Internal medicine
Chemotherapy
Medicine
Oncology
urothelial cancer
open label
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations